Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Weight Loss and Food and Drug Administration
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, sparking legal and industry pushback.
FiercePharma
2d
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
12h
on MSN
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
3h
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
FiercePharma
13d
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
3h
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
2d
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
5d
on MSN
Wegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Discover Magazine
4d
Off-Brand Ozempic, Zepbound and Other Products Carry Undisclosed Risks
As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be safe or effective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback